According to a recent report by Grand View Research, Inc., the global pulmonary arterial hypertension (PAH) market is projected to reach USD 11.02 billion by 2030. From 2024 to 2030, the market is expected to grow at a robust compound annual growth rate (CAGR) of 5.4%. This growth is primarily driven by factors such as the rising prevalence of PAH, continued drug development, technological advancements, regulatory approvals, and strategic initiatives from leading companies.
The COVID-19 pandemic had a significant impact on the market, introducing uncertainty and slowing growth. Key challenges during the pandemic included operational disruptions, supply chain delays, and difficulties in conducting clinical trials. Additionally, market participants reported a decline in both new patient initiations and prescription volumes in 2020.
For example, the second quarter of 2020 saw decreased sales of Remodulin, Tyvaso, and Orenitram, largely due to reduced new patient starts. However, these numbers gradually rebounded to pre-pandemic levels in the latter half of the year. In response to pandemic-related challenges, companies adopted several strategies, such as maintaining strong financial health, ensuring product availability, sustaining uninterrupted distribution, and continuing R&D activities. Despite initial disruptions, overall PAH drug sales remained relatively stable due to these efforts.
Regulatory approvals continue to support market expansion. These include approvals for expanded indications, the introduction of generics, and advancements in drug delivery systems. For instance, in March 2021, United Therapeutics’ Tyvaso received FDA approval for treating pulmonary hypertension associated with interstitial lung disease. In February 2021, the company also launched the Remunity Pump in the U.S., a subcutaneous delivery system for its flagship product, Remodulin.
Get a preview of the latest developments in the Global Pulmonary Arterial Hypertension Market! Download your FREE sample PDF today and explore key data and trends
PAH occurs when the pulmonary arteries thicken or grow rigid.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/pulmonary-arterial-hypertension-pah-market/request-sample Market Synopsis of Pulmonary Arterial Hypertension Market: Globally the PAH market is segmented on the basis of Drug class, Surgery, and region.
On the basis of Drug class, the global PAH market is classified into Endothelin Receptor Antagonists (ERAs) (Tracleer, Opsumit, Letairis)- These medications reverse the effect of endothelin, a substance in the walls of blood vessels that causes them to narrow; Prostacyclin and Prostacyclin Analogs- were the first medications approved by the U.S. FDA for the treatment of PAH.
These drugs have superiority over existing therapy options with respect to the therapeutic efficacy, route of administration, and side-effects.
In the U.S., the Orphan Drug Act (ODA) encourages pharmaceutical industries to develop orphan drugs by offering benefits such as tax credits, research grants, and orphan drug exclusivity of seven years.
Geographically, PAH market is segmented into North America, Europe, Asia Pacific, Latin America, MEA, and Rest of the World.
